Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental combo targets Hard-to-Treat cancers

NCT ID NCT03994601

Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested an experimental drug called BMS-986288, both by itself and combined with the immunotherapy nivolumab (Opdivo), in 219 people with advanced solid tumors that had worsened after standard treatments. The main goal was to check safety and tolerability, and to find the right dose. The study is now complete, but results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
BMS-986288 (an experimental drug) and nivolumab (Opdivo, an immunotherapy)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is an early-phase trial focused on safety, so it is not yet known if the drug combination works. Side effects could be serious, and the results may not lead to a widely available treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

219 people

The number who actually took part.

Started

Sep 2019

Finished

Aug 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologic or cytologic confirmation of select solid tumor that is advanced (metastatic, recurrent, and/or unresectable) with measurable disease and have at least 1 lesion accessible for biopsy * Eastern Cooperative Oncology Group Performance Status of 0 or 1 * Received, and then progressed, relapsed, or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting according to select solid tumor histologies Exclusion Criteria: * Active, known or suspected autoimmune disease * Active malignancy requiring concurrent intervention * Primary Central Nervous System (CNS) malignancies or tumors with CNS metastasis as the only site of disease, will be excluded Other protocol-defined inclusion/exclusion criteria apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced cancer

Contacts and locations

Locations

  • Centre Hospitalier intercommunal de Toulon La Seyne sur Mer

    Toulon, 83100, France

  • Local Institution - 0001

    Hackensack, New Jersey, 07601, United States

  • Local Institution - 0002

    Baltimore, Maryland, 21287, United States

  • Local Institution - 0004

    St Louis, Missouri, 63110, United States

  • Local Institution - 0005

    Aurora, Colorado, 80045, United States

  • Local Institution - 0006

    Toronto, Ontario, M5G 2M9, Canada

  • Local Institution - 0008

    ABB, Distrito Federal, C1199, Argentina

  • Local Institution - 0009

    Santiago, Santiago Metropolitan, 8420383, Chile

  • Local Institution - 0010

    Viña del Mar, Valparaiso, 2520598, Chile

  • Local Institution - 0011

    Ciudad Autónoma de Buenos Aires, Buenos Aires, 1426, Argentina

  • Local Institution - 0012

    CABA, Distrito Federal, C1430, Argentina

  • Local Institution - 0013

    Río Cuarto, Córdoba Province, 5800, Argentina

  • Local Institution - 0014

    Córdoba, Córdoba Province, X5000HXL, Argentina

  • Local Institution - 0015

    Paris, 75248, France

  • Local Institution - 0016

    Buenos Aires, C1280AEB, Argentina

  • Local Institution - 0017

    Buenos Aires, 1431, Argentina

  • Local Institution - 0018

    Bron, 69677, France

  • Local Institution - 0019

    Santiago, Santiago Metropolitan, 7510032, Chile

  • Local Institution - 0022

    Saint-Herblain, Loire-Atlantique, 44800, France

  • Local Institution - 0023

    Madrid, 28041, Spain

  • Local Institution - 0024

    Majadahonda, 28222, Spain

  • Local Institution - 0025

    Valencia, 46026, Spain

  • Local Institution - 0026

    Marseille, 13915, France

  • Local Institution - 0028

    Ancona, 60126, Italy

  • Local Institution - 0031

    Milan, 20162, Italy

  • Local Institution - 0033

    Catanzaro, 88100, Italy

  • Local Institution - 0034

    Bordeaux, Gironde, 33075, France

  • Local Institution - 0035

    Santiago, Santiago Metropolitan, 7620002, Chile

  • Local Institution - 0036

    Santiago, Santiago Metropolitan, 7500921, Chile

  • Local Institution - 0038

    Padova, Veneto, 35128, Italy

  • Local Institution - 0039

    Roma, 00168, Italy

  • Local Institution - 0040

    Milan, Lombardy, 20133, Italy

  • Local Institution - 0042

    Montreal, Quebec, H2X 0A9, Canada

  • Local Institution - 0046

    Montreal, Quebec, H3T 1E2, Canada

  • Local Institution - 0050

    Orange, California, 92868-3201, United States

  • Local Institution - 0054

    Barcelona, Catalunya [Cataluña], 08036, Spain

  • Local Institution - 0055

    Seville, 41013, Spain

  • Local Institution - 0056

    Barcelona, Barcelona [Barcelona], 08035, Spain

  • Local Institution - 0074

    Buenos Aires, Buenos Aires F.D., C1096AAS, Argentina

  • Local Institution - 0075

    Costa Mesa, California, 92627, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.